Abstract
The effect of misoprostol (Cytotec®), an cytoprotective agent, in preventing mucosal damage caused by piroxicam and ampiroxicam was evaluated in 20 patients requiring NSAID. Patients with normal endoscopic findings were administered both misoprostol 600μg and ampiroxicam 27 mg for 2 weeks. Gastroduodenal mucosal damage was significantly less in the misoprostol administered group than the only ampiroxicam administered group (p<0.05) . There was a significantly lower incidence of development of gastroduodenal mucosal damage in the non-habit of drinking group than the group of habit of drinking. As to the preferential site for the development of thesee lesions, the commonest site was the duodenum. Against lesions developed in the duodenal, significantly higher prophylactic effect was observed for the misoprostol administered group.It is considered from these results that misoprostol exists a highly prophylactic effect against piroxicam and ampiroxicam induced upper gastrointestinal mucosal damage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
